HLA-DR binding peptides and their uses

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 10556943
APP PUB NO 20170342126A1
SERIAL NO

15381454

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH200 FIRST STREET SW ROCHESTER MN 55905

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Beebe, Melanie Apex, US 3 25
Disis, Mary L Renton, US 36 726
Fikes, John D San Diego, US 24 306
Ishioka, Glenn San Diego, US 10 76
Knutson, Keith L Jacksonville, US 15 61

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 11, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 11, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00